Ruxience Copay Assistance

지원 작동 방식

비교할 수 없는 완벽한 편의성을 통해 환자의 전문 약국 경험을 간소화합니다.

1. 보장 범위/혜택 확인
당사의 전문 청구자 팀은 실제 비용을 최소화하는 가장 적합한 보장 방안을 찾아드립니다.
2. AmeriPharma®로 처방전 전송
우리는 귀하의 이전 약국이나 처방자와 협력하여 처방을 처리하므로 전환이 빠르고 쉽습니다.
3. 사전 승인
저희 전문가 팀은 24~72시간 내에 귀하의 보험 회사로부터 승인을 받습니다.
4. 공제금 지원 및 재정 지원
저희는 재정 지원을 확보하고 본인 부담금, 본인 부담금, 그리고 높은 공제액을 줄여드립니다. 현재까지 AmeriPharma® Specialty Care는 환자분들을 위해 1TP4억 4,700만 달러(약 1,447억 5,500만 원)의 재정 지원을 확보했습니다.
5. 간호 케어 조정
AmeriPharma®는 집에서 주입을 위해 전문 간호사 중 한 명과 일정을 조정하고 조정할 때 귀하의 일정과 가정 환경을 우선시합니다.
6. 배송 조정
의약품은 항상 특정 배송 요건을 엄격히 준수하여 배송됩니다. 익일 배송 및 익일 배송은 고객님의 일정에 맞춰 조정됩니다.

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/pharmacist.jpg

What Is Ruxience?

Ruxience is a CD20-directed cytolytic antibody used to treat certain autoimmune diseases and types of cancer. It is an FDA- approved biosimilar to Rituxan (rituximab).

Patients should be under the care of a clinician experienced with using rituximab for the specific indication they are being treated for.

Pretreatment immunizations

When feasible, administer appropriate immunizations 4 weeks or more before starting therapy.

Prophylaxis against opportunistic infection and viral reactivation may be warranted during and up to 12 months after completion of rituximab therapy.

Premedication

The manufacturer’s labeling recommends premedicating about 30 minutes prior to administration with acetaminophen, an antihistamine, and methylprednisolone 100 mg (IV) or equivalent for adults.

https://ameripharmaspecialty.com/wp-content/uploads/2024/02/block_image_1.jpg

What is Ruxience Used to Treat?

Ruxience is used to treat patients with:

Non-Hodgkin’s Lymphoma (NHL)
- Relapsed or refractory, follicular or low grade, CD20-positive B-cell NHL as a single agent.
- Previously untreated CD20-positive, follicular, B-cell NHL in combination with first-line chemotherapy. Also used in patients achieving a partial or complete response to a rituximab product in combination with chemotherapy, as a single-agent maintenance therapy.
- Non-progressing (including stable disease), CD20-positive, low-grade B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy.
- Previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or another anthracycline-based chemotherapy regimen.
Chronic Lymphocytic Leukemia (CLL)
- Previously treated and previously untreated CD20-positive CLL in combination with fludarabine and cyclophosphamide.
Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids.
다발성 경화증
류머티스성 관절염

공제금 및 재정 지원

AmeriPharma™ 전문 약국은 환자와 그 가족의 재정적 부담을 덜어줍니다.

고급 소프트웨어는 귀하에게 최고 수준의 재단 프로그램을 매칭하기 위해 자금원을 찾아줍니다.
당사의 공제금 지원 전문가 중 한 명이 신청 절차를 도와드립니다.
자금 지원 상태에 대한 자동 업데이트가 귀하와 귀하의 의사에게 전송됩니다.

https://ameripharmaspecialty.com/wp-content/uploads/2024/05/doctor-patient.jpg

Ruxience Dosing Information

Immune thrombocytopenia (alternative agent) (off-label use):

IV dose: 375 mg/m2 once weekly for 4 doses.

Rheumatoid arthritis (Rituxan and rituximab biosimilars) (alternative agent):

Initial IV dose: 1 g once every 2 weeks for 2 doses; subsequent courses of 1 g once every 2 weeks for 2 doses may be administered every 24 weeks or as indicated based on clinical evaluation, but no sooner than every 16 weeks.

Multiple sclerosis (off-label use):

IV dose: 1 g once every 2 weeks for 2 doses; then repeat 1 g once every 6 to 12 months. Alternatively, administer 500 mg to 1 g once every 6 to 12 months.

Myasthenia gravis, refractory or muscle-specific tyrosine kinase antibody-positive (off-label use):

IV dose: 1 g once every 2 weeks for 2 doses or 375 mg/m2 once weekly for 4 weeks; full or partial course may be repeated at preplanned intervals (e.g., 6 months) or as clinically indicated based on symptoms and lymphocyte recovery.